Applications of (S)-4-(4-Aminobenzyl)-2(1H)-Oxazolidinone in Industrial Manufacturing

(S)-4-(4-Aminobenzyl)-2(1H)-Oxazolidinone serves as a specialized chemical intermediate primarily in the pharmaceutical sector and select advanced material synthesis. As an original manufacturer, we focus on supplying this chiral oxazolidinone scaffold for mature downstream processes, where its controlled introduction and functional group compatibility are essential for successful formulation and consistent batch quality.

1. Active Pharmaceutical Ingredient (API) Synthesis: Oxazolidinone-Class Antibiotics

Advanced facilities engaged in the production of oxazolidinone antibiotic APIs rely on this raw material as a pivotal asymmetric building block. Its stereospecific configuration supports the construction of pharmacologically active moieties, directly impacting enantiopurity and final product compliance. Our internal customer feedback indicates direct oligomerization or ring closure steps extensively use this compound, where real-time chiral analysis ensures regulatory batch tracking remains within specification.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• U.S. Pharmacopeia (USP) General Chapter
• European Pharmacopoeia Monograph 01/2008:2456
• FDA 21 CFR Part 210/211 (Current Good Manufacturing Practice for Drugs)

Typical usage ratio

• 0.8%–2.5% w/w per stage in multi-step API synthesis; adjusted based on batch yield, target molecular complexity, and stereo-demand of final linezolid or tedizolid compounds

Downstream process integration

• Introduced during the ring assembly or amidation stages in the core antibiotic synthesis flow; typically subjected to hydrogenation, protection/deprotection, and subsequent coupling in stepwise pharmaceutical pipeline

Final product types

• Linezolid API
• Radezolid API
• Tedizolid phosphate API
• Other pipeline oxazolidinone derivatives for gram-positive antibacterial therapy

2. Chiral Auxiliary for Asymmetric Synthesis

Process developers in specialty chemical manufacturing use this compound as a chiral auxiliary, capitalizing on its ability to induce stereocontrol in various asymmetric catalytic reactions. Its amino-benzyl substituent and oxazolidinone core enable the selective construction of carbon–carbon and carbon–heteroatom bonds, directly contributing to higher enantioselectivity in high-value agrochemical, fine chemical, and preclinical drug molecule syntheses.

Industry compliance standards

• ISO 9001:2015 for Quality Management Systems
• OECD Principles of Good Laboratory Practice (GLP) for R&D Results
• Chemical Control Law (TSCA in the US, REACH in the EU)
• Responsible Care® Management System

Typical usage ratio

• 0.5–1.0 molar equivalents per substrate; stoichiometry adjusted based on target stereoselectivity and auxiliary recovery steps

Downstream process integration

• Added during enantioselective alkylation, reductive amination, or aldol condensation in catalyst-controlled flow chemistry; subject to auxiliary cleavage for final product isolation if required

Final product types

• Chiral intermediates for pharmaceutical pipeline research
• Advanced agrochemical actives with defined stereochemistry
• Custom fine chemical intermediates for contract synthesis

3. Intermediate in Peptidomimetic Synthesis

Biotechnology manufacturers employ this compound as a scaffold for preparing constrained peptide-mimicking frameworks. The oxazolidinone ring, coupled with the aminobenzyl group, supports backbone modifications, conferring critical conformational stability to next-generation enzyme inhibitors and receptor modulating agents developed for therapeutic and diagnostic use.

Industry compliance standards

• Good Manufacturing Practice according to EudraLex Volume 4
• ICH Q11 (Development and Manufacture of Drug Substances)
• USP General Chapter <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products
• ISO 13485:2016 for Medical Device Intermediates (where relevant)

Typical usage ratio

• 0.2–1.4 equivalents depending on peptide chain length and degree of backbone modification; use rate determined by target ring incorporation step

Downstream process integration

• Utilized during solid-phase or solution-phase assembly prior to cyclization or side-chain protection, especially in constrained or macrocyclic peptidomimetic synthesis

Final product types

• Protease inhibitor leads for pharmaceutical R&D
• Mimetic scaffolds for peptide-drug conjugates
• Conformationally stabilized enzyme modulators

4. Fine Chemical Intermediate for Heterocyclic Compound Libraries

Specialty fine chemical producers integrate this material into development pipelines for heterocyclic compound libraries utilized in medicinal chemistry screening and advanced material exploration. Its rigid, chiral backbone and readily accessible amino functionality facilitate the rapid assembly of core heterocycles via nucleophilic substitution or condensation reactions.

Industry compliance standards

• ISO 9001:2015 for chemical synthesis quality management
• REACH Registration (EC 1907/2006) for market authorization in the EU
• Globally Harmonized System (GHS) for labeling and handling
• Local occupational health and safety regulations (e.g., OSHA in the US, Hazardous Substances Ordinance in China)

Typical usage ratio

• 0.4–1.2 equivalents per reaction sequence, modulated by target scaffold and number of diversification points needed

Downstream process integration

• Introduced during combinatorial synthesis workflows, including automated solution-phase or solid-phase parallel reactor platforms, followed by rapid purification and analytical validation

Final product types

• Fragment-based drug discovery core heterocycles
• Screening sets for target validation in high-throughput screening
• Diversified heterocycle libraries for material science R&D